Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Articles

Inhibition of In Vitro Lymphocyte Response by Streptozotocin-induced Diabetic Rat Serum: A Function of Very-Low-Density Lipoproteins

  1. David S Chi,
  2. Dianne L Berry,
  3. Karen A Dillon and
  4. Bradley W Arbogast
  1. Department of Internal Medicine, Quillen-Dishner College of Medicine, East Tennessee State University Johnson City, Tennessee 37614
  1. Address reprint requests to Dr. David S. Chi at the above address.
Diabetes 1982 Dec; 31(12): 1098-1104. https://doi.org/10.2337/diacare.31.12.1098
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Immune function is generally reported to be impaired in uncontrolled diabetes mellitus. We have previously reported that very-low-density lipoproteins (VLDL) from diabetic rat serum injure endothelial cells in vitro. Thus, we wanted to determine if VLDL would also injure lymphocytes and impair the immunity of the streptozotocin-induced diabetic rat. The immunologie functions of spleen cells from normal and diabetic rats were studied using the in vitro mitogenic stimulation assay and mixed lymphocyte responses (MLR). The effects of diabetic serum and VLDL isolated from diabetic rat serum on normal spleen cells were also determined. Both the absolute peripheral blood leukocyte (PBL) and spleen cell numbers of diabetic rats were significantly decreased from those of normal rats (P < 0.02). In PBL there was a decreased percentage of lymphocytes and increased percentage of neutrophils (both P < 0.02). The mitogenic stimulation responses of spleen cells from diabetic rats were consistently lower than normal for 3 of the 4 mi-togens used. The responses of con A-stimulated lymphocytes from diabetic spleens were significantly different (P < 0.025) from normal spleen cells. The MLR appeared to be normal. The decreased mitogenic responses of cells from diabetic spleens were not due to the induction of suppressor cells. Diabetic rat serum inhibited the proliferation of both control and mitogen-stimulated normal rat lymphocytes. Addition of increasing amounts of VLDL, isolated from diabetic serum, to normal spleen cell cultures also resulted in an exponential decrease in 3H-thymidine incorporation. Complete inhibition of the response of normal spleen cells to PHA was achieved at a VLDL triglyceride concentration of 262 μg/ml. The 4-day-old lym-phyocyte cultures incubated with VLDL at 262-μg/ml concentration were only 11% viable, which was significantly lower than the 58% viability of control cultures without VLDL (P < 0.005). Removal of VLDL from diabetic rat serum eliminated the toxic effect of diabetic serum on spleen cell cultures. Reconstitution of the infra nata n t fraction (d > 1.006) with the VLDL fraction (d < 1.006) restored the toxic activity. These results indicate that the inhibitory effect of diabetic rat serum on the mitogenic responses of normal rat spleen cells is due to the toxicity Of VLDL.

  • Received April 29, 1982.
  • Revision received July 6, 1982.
  • Copyright © 1982 by the American Diabetes Association

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this Issue

December 1982, 31(12)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of In Vitro Lymphocyte Response by Streptozotocin-induced Diabetic Rat Serum: A Function of Very-Low-Density Lipoproteins
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Inhibition of In Vitro Lymphocyte Response by Streptozotocin-induced Diabetic Rat Serum: A Function of Very-Low-Density Lipoproteins
David S Chi, Dianne L Berry, Karen A Dillon, Bradley W Arbogast
Diabetes Dec 1982, 31 (12) 1098-1104; DOI: 10.2337/diacare.31.12.1098

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Inhibition of In Vitro Lymphocyte Response by Streptozotocin-induced Diabetic Rat Serum: A Function of Very-Low-Density Lipoproteins
David S Chi, Dianne L Berry, Karen A Dillon, Bradley W Arbogast
Diabetes Dec 1982, 31 (12) 1098-1104; DOI: 10.2337/diacare.31.12.1098
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Essential Fatty Acids in the Management of Impaired Nerve Function in Diabetes
  • Foreword
  • Pharmacological Strategies to Prevent Macrovascular Disease in NIDDM
Show more Articles

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.